BioSpace News Archive

KalVista Pharmaceuticals, Inc. announced the acceptance of multiple abstracts at the 2023 US HAEA National Summit taking place in Orlando, Florida from July 20-23.

Asensus Surgical, Inc. today announced that a leading United States-based hospital, has initiated a Senhance Surgical System program for use within their pediatric surgery department.

CureVac N.V. today announced that Dr. Igor Splawski, CureVac’s Chief Scientific Officer, will step down effective July 14, 2023 to return to early-stage research in the United States.

Alphyn Biologics released interim results today from the second cohort of its Phase 2a clinical trial program of AB-101a, a novel topical candidate for atopic dermatitis (AD).

CurvaFix, Inc ., a developer of medical devices to repair fractures in curved bones, today announced the close of a $39 million equity financing led by MVM Partners with participation from Sectoral Asset Management and other existing investors.

ProMIS Neurosciences Inc. is pleased to announce that it has completed its continuance (the “ Continuance ”) from the Canada Business Corporations Act into the Province of Ontario under the Business Corporations Act (Ontario) as of July 13, 2023.

ZyVersa Therapeutics, Inc. announces that Stephen C. Glover, Co-Founder, Chairman, Chief Executive Officer, and President, has been invited to speak at the H.C. Wainwright 2nd Annual Kidney Conference being held virtually on July 25, 2023.

SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced it has been granted an approval from the Israeli Medical Cannabis Agency (“IMCA”) at the Israeli Ministry of Health to conduct its clinical trial for SCI-210 in children suffering from autism spectrum disorder (“ASD”).

Relievant Medsystems today announced the release of next-generation Intracept ® Access Instruments.

Eli Lilly and Company (NYSE: LLY) and Versanis Bio today announced a definitive agreement for Lilly to acquire Versanis, a private clinical-stage biopharmaceutical company focused on the development of new medicines for the treatment of cardiometabolic diseases.